Lack of evidence for the μ‐opioid receptor splice variant MOR1 C in rats

We previously reported the existence of MOR1 C mRNA and MOR1 C ‐immunoreactivity (‐ir) in rats. However, the sequence that we reported for rat MOR1 C appears not to be present in the rat genome. We have therefore reexamined whether MOR1 C mRNA or MOR1 C ‐ir exist in rats. We used reverse‐transcription polymerase chain reaction (RT‐PCR) to attempt to amplify MOR1, MOR1 A , MOR1 B , the rat MOR1 C sequence we previously reported, and MOR1 C1 and MOR1 C2 (which have recently been reported to exist in rats). In RNA extracted from rats, we were able to demonstrate PCR products representing MOR1, MOR1 A , and MOR1 B splice variants. All three products were confirmed as related to MOR1 by Southern blot. However, we were unable to detect either the MOR1 C product reported previously by us or the MOR1 C ‐like products reported to exist in rats by others. In RNA extracted from mice we were able to detect MOR1, MOR1 A , MOR1 B , and MOR1 D ‐like products. To test the specificity of our MOR1 C antiserum, we examined MOR1 C ‐ir in control and knockout mice. MOR1 C ‐ir had a distribution in control mice similar to that previously reported in rats, including coexisting with vGLUT2. However, although MOR1‐ir was absent in MOR1 knockout mice, the density and distribution of MOR1 C ‐ir were unchanged, suggesting that the antiserum crossreacts with another molecule in tissue. We find no evidence for MOR1 C mRNA in rats. Furthermore, we conclude that MOR1 C ‐ir represents crossreactivity. J. Comp. Neurol. 517:452–458, 2009. © 2009 Wiley‐Liss, Inc.